Ftse Mib
34.825,01
-1,62%
DAX
18.768,96
0,33%
S&P 500
5.308,13
0,09%
NASDAQ
16.794,87
0,65%
Bitcoin
71.049,09
-0,56%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Aptorum Group Ltd (APM) Aptorum Group Ltd (APM) Notizie

APM

Aptorum (APM)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:APM
DataOraFonteTitoloSimboloCompagnia
30/04/202415:15Business WireAptorum Group Limited Reports 2023 Fiscal Year End Financial Results and Provides Business UpdateNASDAQ:APMAptorum Group Ltd
06/03/202414:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:APMAptorum Group Ltd
06/03/202414:00Business WireAptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a Split-off Agreement to Separate its Legacy BusinessNASDAQ:APMAptorum Group Ltd
22/12/202322:30Business WireAptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023NASDAQ:APMAptorum Group Ltd
21/12/202322:30Business WireAptorum Group Limited Announces Results of 2023 Annual General Meeting of ShareholdersNASDAQ:APMAptorum Group Ltd
21/11/202316:25Edgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:APMAptorum Group Ltd
16/11/202317:00Business WireAptorum Group Limited to Hold Annual General Meeting of Shareholders on December 20, 2023NASDAQ:APMAptorum Group Ltd
10/08/202308:57Business WireAptorum Group Receives Nasdaq Approval to Transfer Listing to Nasdaq Capital MarketsNASDAQ:APMAptorum Group Ltd
22/06/202314:00Business WireAptorum Group Updates on a Phase 1b/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for NeuroblastomaNASDAQ:APMAptorum Group Ltd
09/06/202322:31Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:APMAptorum Group Ltd
09/06/202322:30Business WireAptorum Group Limited Announces Voluntary Delisting from Euronext ParisNASDAQ:APMAptorum Group Ltd
24/05/202315:01Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:APMAptorum Group Ltd
22/05/202312:02Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:APMAptorum Group Ltd
17/05/202322:31Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:APMAptorum Group Ltd
05/05/202322:31Business WireAptorum Group Receives Nasdaq Notification of Minimum Stockholders’ Equity DeficiencyNASDAQ:APMAptorum Group Ltd
03/05/202315:29Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:APMAptorum Group Ltd
01/05/202314:00Business WireAptorum Therapeutics Limited Enters Into Letter of Intent and Term Sheet with Universal Sequencing Technology Corporation to Merge with Aptorum Group’s Subsidiary Paths Innovations LimitedNASDAQ:APMAptorum Group Ltd
28/04/202315:44Business WireAptorum Group Limited Reports 2022 Fiscal Year End Financial Results and Provides Business UpdateNASDAQ:APMAptorum Group Ltd
27/03/202321:30Business WireLe groupe Aptorum signe une lettre d'intention et une liste de conditions pour l'acquisition d'U groupNASDAQ:APMAptorum Group Ltd
27/03/202313:00Business WireAptorum Group Enters into Letter of Intent and Term Sheet To Acquire U GroupNASDAQ:APMAptorum Group Ltd
03/03/202313:30Business WireAptorum Group Announces Completion of End of Phase 1 (EOP1) Meeting with US FDA on its SACT-1, a Repurposed Small Molecule Drug Targeting NeuroblastomaNASDAQ:APMAptorum Group Ltd
03/03/202313:30Business WireAptorum Group Announces Completion of Pre-IND Discussions with US FDA on its ALS-4, a First-in-Class Small Molecule Drug Targeting Methicillin Resistant Staphylococcus AureusNASDAQ:APMAptorum Group Ltd
02/03/202322:31Edgar (US Regulatory)Amended Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k/a)NASDAQ:APMAptorum Group Ltd
02/03/202313:30Business WireAptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in ChinaNASDAQ:APMAptorum Group Ltd
10/02/202322:30Business WireAptorum Group Regains Compliance with Nasdaq Minimum Bid Price and Receives Nasdaq Notification of Minimum Market Value of Publicly Held Shares DeficiencyNASDAQ:APMAptorum Group Ltd
06/02/202316:08Business WireAptorum Group Limited to Hold Special Extraordinary Meeting of Shareholders on February 21, 2023NASDAQ:APMAptorum Group Ltd
20/01/202314:00Business WireAptorum Group Announces 1-for-10 Reverse Stock SplitNASDAQ:APMAptorum Group Ltd
17/01/202312:33Edgar (US Regulatory)Amended Annual and Transition Report (foreign Private Issuer) (20-f/a)NASDAQ:APMAptorum Group Ltd
04/01/202319:50Business WireAptorum Group annonce la publication d’un document co-écrit sur sa technologie PathsDx, un flux rapide de séquençage métagénomique objectif à faible profondeur pour le diagnostic des maladies infectieuses basé...NASDAQ:APMAptorum Group Ltd
04/01/202315:00Business WireAptorum Group Announces Publication of a Co-authored Paper on its PathsDx Technology - a Rapid-Turnaround Low-Depth Unbiased Metagenomics Sequencing Workflow for Liquid Biopsy based Diagnosis of Infectious Diseases on Illumina PlatformsNASDAQ:APMAptorum Group Ltd
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:APM

La tua Cronologia

FX
EURTRY
Euro vs TRY
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network